Shield Therapeutics (STU:1JS) Forward PE Ratio: 8.18 (As of Jul. 08, 2026)


What is Shield Therapeutics Forward PE Ratio?

Shield Therapeutics STU:1JS Forward PE Ratio is 8.18 as of Jul. 08, 2026. The stock has 5 warning signs investors should review. Among 408 Drug Manufacturers companies, Shield Therapeutics ranks better than 79.66% on this metric.

Shield Therapeutics's Forward PE Ratio for today is 8.18.

Shield Therapeutics's PE Ratio without NRI for today is 0.00.

Shield Therapeutics's PE Ratio (TTM) for today is 0.00.

Shield Therapeutics  (STU:1JS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Shield Therapeutics Forward PE Ratio Related Terms

Shield Therapeutics Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Forward PE Ratio Chart

Shield Therapeutics Annual Data
Trend
Forward PE Ratio

Shield Therapeutics Semi-Annual Data
2020-06
Forward PE Ratio 45.05

STU:1JS vs ZTS, UTHR, VTRS: Forward PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics Forward PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Forward PE Ratio falls into.


Shield Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 8.18 mean?
Shield Therapeutics (STU:1JS) has a Forward PE Ratio of 8.18 as of Jul. 08, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #83 out of 408 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Shield Therapeutics' Forward PE Ratio too high?
Shield Therapeutics' current Forward PE Ratio is 8.18. The Drug Manufacturers industry median Forward PE Ratio is 17.36. Shield Therapeutics' value of 8.18 is 52.9% below this industry median. Based on the distribution chart, Shield Therapeutics ranks #83 out of 408 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shield Therapeutics' Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #83 out of 408 companies for Forward PE Ratio. This places Shield Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.36. Shield Therapeutics' value of 8.18 is 52.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.36, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current Forward PE Ratio of 8.18 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Forward PE Ratio is 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Forward PE Ratio is 8.18 and 52.9% below the Drug Manufacturers industry median of 17.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Forward PE Ratio is 8.18 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.